Effect of PolyGlycopleX (PGX) consumption on blood lipid profiles in healthy, Low CVD risk overweight adults

Solah, V.A., Kerr, D.A., Irawati, D., Hunt, W., Meng, X., Gahler, R.J., Fenton, R.J., Fenton, H.K., Johnson, S.K. and James, A.P. (2019) Effect of PolyGlycopleX (PGX) consumption on blood lipid profiles in healthy, Low CVD risk overweight adults. Nutrients, 11 (4). p. 717.

Abstract

Raised blood lipid levels are associated with a risk of a cardiovascular disease (CVD). Moderate reductions in several CVD factors such as total, low-density lipoprotein (LDL) cholesterol and non-high-density lipoprotein (non-HDL) cholesterol concentrations may be more effective in reducing overall risk than a major reduction in just one. A blind, randomised controlled trial was conducted with 120 healthy overweight (BMI 25–30) adults aged 25–70 years who were non-smokers, not diabetic and of low risk of cardiovascular disease, as assessed by the Framingham risk equation. Participants consumed 4.5 g PolyGlycopleX (PGX) as softgel capsules (PGXS) or 5 g PGX granules (PGXG) or 5 g rice flour (RF) with meals three times a day for 12 weeks. Total, LDL and non-HDL cholesterol were all significantly reduced (−6%, −5% and −3.5%, respectively) post the PGX granule treatment; however, PGX in softgel capsule form did not affect blood lipid profiles. Daily consumption of PGX granules in overweight low CVD risk adults produced lipid changes indicating a CVD preventative benefit.

Item Type:	Journal Article
Publisher:	MDPI
Copyright:	© 2019 MDPI
URI:	http://researchrepository.murdoch.edu.au/id/eprint/56535

Item Control Page

Downloads